Related Experiment Video
Updated: Jul 16, 2026

Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids
Published on: October 14, 2019
A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress
Irvin M Modlin1, Manish C Champaneria, Anthony K C Chan
1Gastrointestinal Pathobiology Research Group, Yale University School of Medicine, New Haven, Connecticut 06520-8062, USA.
Objectives:
Small intestinal neuroendocrine tumors (SI-NETs) are the most common gastrointestinal neuroendocrine tumor, but their natural history and outcome remain poorly defined, which hinders both the prediction of disease progression and appropriate therapeutic options. We examined patterns, incidence, prognosis, and outcomes of these tumors over a 30-yr period.
Methods:
Data were extracted from the NCI's SEER registry (1973-2002). Incidence rates, distribution, and 5-yr survival rates were analyzed and adjusted (U.S. decennial census data).
Results:
Of the 18,641 NETs, 3,911 (21.0%) were SI-NETs, of which 1,953 (49.6%) were ileal. Since 1973, both SI-NET and its ileal variant have increased annually by 3.8% and 2.1%, respectively. Ileal tumors, as a percentage of SI tumors, have increased from 52% to 63.6%. The age-adjusted incidence of ileal, small intestinal, and digestive system NETs has increased 225%, 460%, and 720% over 30 yr. Ileal tumors have specifically increased in prevalence in white (274%) and black (500%) men and women (213% and 286%, respectively); an overall increase of fourfold in blacks and 2.4-fold in whites. Although 83.3% of SI-NETs were staged, 83.7% were histologically ungraded. Five-year survival rates for SI-NETs were 62.6 +/- 1% (all stages), 73.8% (localized), 72% (regional), and 43.2% (distant). These have not significantly altered since 1973 (P= 0.11).
Conclusions:
SI-NETs have increased, particularly in men and in the black population, which may be due to in vivo changes, increased clinical and pathological awareness, or increased detection of tumors. SI-NETs are malignant, diagnosed late, and survival rates have remained unchanged over 30 yr.
Insights
Small intestinal neuroendocrine tumors (SI-NETs) incidence has significantly increased, especially in men and Black populations. Despite this rise, survival rates for SI-NETs have remained unchanged over 30 years, indicating late diagnoses.
Area of Science:
- Gastroenterology
- Oncology
- Epidemiology
Background:
- Small intestinal neuroendocrine tumors (SI-NETs) are the most common gastrointestinal neuroendocrine tumors.
- The natural history and outcomes of SI-NETs are not well-defined, impacting disease progression prediction and treatment.
- Understanding trends in SI-NETs is crucial for improving patient care and therapeutic strategies.
Purpose of the Study:
- To examine the patterns, incidence, prognosis, and outcomes of SI-NETs over a 30-year period.
- To identify demographic and temporal trends in SI-NET occurrence.
- To assess changes in survival rates for SI-NETs.
Main Methods:
- Utilized data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registry from 1973 to 2002.
- Analyzed incidence rates, tumor distribution, and 5-year survival rates.
- Adjusted analyses using U.S. decennial census data for accurate population-based rates.
Main Results:
- SI-NETs constituted 21.0% of all neuroendocrine tumors (NETs), with 49.6% originating in the ileum.
- Annual incidence of SI-NETs and ileal NETs increased by 3.8% and 2.1%, respectively, since 1973.
- Age-adjusted incidence of ileal and small intestinal NETs surged by 225% and 460%, with notable increases in Black populations and men; 5-year survival rates remained stable around 62.6% across all stages.
Conclusions:
- The increasing incidence of SI-NETs, particularly in men and Black individuals, may stem from enhanced awareness, detection, or biological factors.
- SI-NETs are malignant tumors often diagnosed at late stages.
- Survival rates for SI-NETs have not improved significantly over the past three decades.
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...